株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

核医学/放射性医薬品の世界市場予測 ~2023年:種類(診断用(SPECT、PET)、治療用(ベータ放射体、アルファ放射体、小線源療法)、用途(癌、甲状腺、心臓)、地域別

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023

発行 MarketsandMarkets 商品コード 209171
出版日 ページ情報 英文 214 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.87円で換算しております。
Back to Top
核医学/放射性医薬品の世界市場予測 ~2023年:種類(診断用(SPECT、PET)、治療用(ベータ放射体、アルファ放射体、小線源療法)、用途(癌、甲状腺、心臓)、地域別 Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023
出版日: 2018年06月14日 ページ情報: 英文 214 Pages
概要

核医学/放射性医薬品の市場規模は、今後5年間(2018年~2023年)に5.9%のCAGR (年間複合成長率) で推移し、2018年に39億5,000万米ドル、2023年に52億6,000万米ドル規模の市場に成長するものと予測されています。癌および心臓病の罹患率・有病率の上昇、医用ラジオアイソトープm-99の需給ギャップ縮小への取組みなどが、今後の核医学/放射性医薬品市場を促進すると予測されています。しかし、放射性医薬品の半減期の短さ、病院予算の削減、高額な医療機器などが、当市場の成長にとって大きな課題となっています。

当レポートでは、世界の核医学/放射性医薬品市場を調査し、市場の概要、種類・用途・処置数・地域別の市場動向、市場規模の推移と予測、成長要因・阻害要因ならびに市場機会・課題の分析、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 核医学/放射性医薬品:市場概要
  • 地域分析 - PET用核医学/放射性医薬品市場:タイプ別
  • 核医学市場のシェア:タイプ別
  • 地域概要

第5章 核医学/放射性医薬品の世界市場:概要

  • イントロダクション
  • 市場ダイナミクス
    • 促進因子
      • 対象疾病の罹患率および有病率の上昇
      • アルファ線放射免疫療法による癌治療
      • 医用ラジオアイソトープm-99の需給ギャップ縮小への取組み
    • 阻害因子
      • 放射性医薬品の半減期の短さ
    • 市場機会
      • 放射性医薬品の神経系疾患への応用
    • 課題
      • 病院予算の削減と高額の設備機器

第6章 核医学/放射性医薬品の世界市場:種類別

  • イントロダクション
  • 診断用核医学/放射性医薬品
    • SPECT用放射性医薬品
      • TC-99M
      • Tl-201
      • Ga-67
      • I-123
      • その他
    • PET用放射性医薬品
      • F-18
      • Ru-82
      • その他
  • 治療用核医学/放射性医薬品
    • アルファ放射体
      • Ra-223
    • ベータ放射体
      • I-131
      • Y-90
      • Sm-153
      • Re-186
      • Lu-177
      • その他
    • 小線源療法
      • I-125
      • Ir-192
      • Pd-103
      • Cs-131
      • その他

第7章 核医学/放射性医薬品の世界市場:用途別

  • イントロダクション
  • 診断用途
    • SPECT用
      • 心臓
      • リンパ腫
      • 神経系
      • 甲状腺
      • その他
    • PET用
      • 心臓
      • 神経系
      • その他
  • 治療用途用
    • 甲状腺
    • 癌の骨転移
    • リンパ腫
    • 内分泌腫瘍
    • その他

第8章 核医学/放射性医薬品の世界市場:処置数別

  • イントロダクション
  • 診断用
    • SPECT用放射性医薬品
    • PET用放射性医薬品
  • 治療用
    • ベータ放射体
    • アルファ放射体
    • 小線源療法同位体

第9章 核医学/放射性医薬品の世界市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
  • その他の地域

第10章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合シナリオ
    • 合意・協力・契約
    • 製品承認
    • 資金調達
    • 買収
    • 事業拡大
    • その他の動向

第11章 企業プロファイル

  • CARDINAL HEALTH 180
  • GE HEALTHCARE
  • CURIUM
  • LANTHEUS MEDICAL IMAGING
  • BAYER
  • BRACCO IMAGING
  • ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • NORDION
  • ADVANCED ACCELERATOR APPLICATIONS

第12章 付録

図表

LIST OF TABLES

  • TABLE 1: NEW REACTORS EXPECTED TO OPEN DURING THE FORECAST PERIOD
  • TABLE 2: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 3: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 4: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 5: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 6: EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 7: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 8: SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 9: NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 10: EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 11: TC-99M MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 12: NORTH AMERICA: TC-99M MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 13: EUROPE: TC-99M MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 14: TL-201 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 15: NORTH AMERICA: TL-201 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 16: EUROPE: TL-201 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 17: GA-67 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 18: NORTH AMERICA: GA-67 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 19: EUROPE: GA-67 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 20: I-123 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 21: NORTH AMERICA: I-123 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 22: EUROPE: I-123 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 23: OTHER SPECT ISOTOPES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 24: NORTH AMERICA: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 25: EUROPE: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 26: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 27: PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 28: NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 29: EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 30: F-18 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 31: NORTH AMERICA: F-18 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 32: EUROPE: F-18 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 33: RU-82 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 34: NORTH AMERICA: RU-82 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 35: EUROPE: RU-82 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 36: OTHER PET ISOTOPES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 37: NORTH AMERICA: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 38: EUROPE: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 39: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 40: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 41: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 42: EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 43: RA-223 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 44: NORTH AMERICA: RA-223 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 45: EUROPE: RA-223 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 46: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 47: BETA EMITTERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 48: NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 49: EUROPE: BETA EMITTERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 50: I-131 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 51: NORTH AMERICA: I-131 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 52: EUROPE: I-131 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 53: Y-90 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 54: NORTH AMERICA: Y-90 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 55: EUROPE: Y-90 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 56: SM-153 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 57: NORTH AMERICA: SM-153 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 58: EUROPE: SM-153 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 59: RE-186 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 60: NORTH AMERICA: RE-186 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 61: EUROPE: RE-186 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 62: LU-177 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 63: NORTH AMERICA: LU-177 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 64: EUROPE: LU-177 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 65: OTHER BETA EMITTERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 66: NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 67: EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 68: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 69: BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 70: NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 71: EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 72: I-125 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 73: NORTH AMERICA: IODINE-125 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 74: EUROPE: IODINE-125 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 75: IR-192 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 76: NORTH AMERICA: IR-192 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 77: EUROPE: IR-192 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 78: PD-103 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 79: NORTH AMERICA: PD-103 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 80: EUROPE: PD-103 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 81: CS-131 MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 82: NORTH AMERICA: CS-131 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 83: EUROPE: CS-131 MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 84: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 85: NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 86: EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 87: SPECT APPLICATIONS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 88: SPECT APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 89: CARDIOLOGY APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 90: LYMPHOMA APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 91: NEUROLOGY APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 92: THYROID APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 93: OTHER SPECT APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 94: PET APPLICATIONS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 95: PET APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 96: ONCOLOGY APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 97: CARDIOLOGY APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 98: NEUROLOGY APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 99: OTHER PET APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 100: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 101: THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 102: THYROID APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 103: BONE METASTASIS APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 104: LYMPHOMA APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 105: ENDOCRINE APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 106: OTHER THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 107: NUCLEAR MEDICINE PROCEDURES MARKET, BY TYPE, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 108: NUCLEAR MEDICINE PROCEDURES MARKET, BY REGION, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 109: DIAGNOSTIC PROCEDURES MARKET, BY TYPE, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 110: DIAGNOSTIC PROCEDURES MARKET, BY REGION, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 111: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 112: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, BY REGION, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 113: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 114: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 115: THERAPEUTIC PROCEDURES MARKET, BY TYPE, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 116: THERAPEUTIC PROCEDURES MARKET, BY REGION, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 117: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 118: BETA EMITTERS MARKET, BY REGION, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 119: ALPHA EMITTERS MARKET, BY REGION, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 120: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 121: BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2016-2023 (THOUSAND PROCEDURES)
  • TABLE 122: NUCLEAR MEDICINE MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 123: NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 124: NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 125: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 126: NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 127: NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 128: NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 129: NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 130: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 131: NORTH AMERICA: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 132: NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 133: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 134: US: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 135: US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 136: US: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 137: US: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 138: US: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 139: US: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 140: US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 141: US: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 142: US: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 143: US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 144: CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 145: CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 146: CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 147: CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 148: CANADA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 149: CANADA: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 150: CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 151: CANADA: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 152: CANADA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 153: CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 154: EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 155: EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 156: EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 157: EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 158: EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 159: EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 160: EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 161: EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 162: EUROPE: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 163: EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 164: EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 165: GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 166: GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 167: GERMANY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 168: GERMANY: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 169: GERMANY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 170: GERMANY: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 171: GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 172: GERMANY: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 173: GERMANY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 174: GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 175: FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 176: FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 177: FRANCE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 178: FRANCE: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 179: FRANCE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 180: FRANCE: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 181: FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 182: FRANCE: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 183: FRANCE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 184: FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 185: UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 186: UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 187: UK: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 188: UK: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 189: UK: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 190: UK: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 191: UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 192: UK: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 193: UK: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 194: UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 195: ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 196: ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 197: ITALY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 198: ITALY: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 199: ITALY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 200: ITALY: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 201: ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 202: ITALY: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 203: ITALY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 204: ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 205: SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 206: SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 207: SPAIN: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 208: SPAIN: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 209: SPAIN: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 210: SPAIN: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 211: SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 212: SPAIN: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 213: SPAIN: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 214: SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 215: ROE: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 216: ROE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 217: ROE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 218: ROE: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 219: ROE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 220: ROE: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 221: ROE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 222: ROE: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 223: ROE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 224: ROE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 225: ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 226: ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 227: ASIA PACIFIC: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 228: ASIA PACIFIC: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 229: ASIA PACIFIC: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 230: ASIA PACIFIC: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 231: ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 232: ASIA PACIFIC: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 233: ASIA PACIFIC: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 234: ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 235: ROW: NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 236: ROW: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 237: ROW: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 238: ROW: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 239: ROW: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 240: ROW: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 241: ROW: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 242: ROW: BETA EMITTERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 243: ROW: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 244: ROW: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 245: AGREEMENTS, PARTNERSHIPS, AND CONTRACTS (2015-2018)
  • TABLE 246: PRODUCT APPROVALS (2015-2018)
  • TABLE 247: FUNDING (2015-2018)
  • TABLE 248: ACQUISITIONS (2015-2018)
  • TABLE 249: EXPANSIONS (2015-2018)
  • TABLE 250: OTHER DEVELOPMENTS (2015-2018)

LIST OF FIGURES

  • FIGURE 1: GLOBAL NUCLEAR MEDICINE MARKET: RESEARCH METHODOLOGY
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: BOTTOM-UP APPROACH
  • FIGURE 4: TOP-DOWN APPROACH
  • FIGURE 5: RESEARCH DESIGN
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: NUCLEAR MEDICINE MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 8: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 9: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 10: RISING INCIDENCE & PREVALENCE OF CANCER & CARDIOVASCULAR DISEASES-KEY FACTOR SUPPORTING MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 11: ONCOLOGY SEGMENT DOMINATED THE NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS IN 2017
  • FIGURE 12: DIAGNOSTICS SEGMENT WILL CONTINUE TO DOMINATE THE NUCLEAR MEDICINE MARKET IN 2023
  • FIGURE 13: ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE NUCLEAR MEDICINE MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 15: DIAGNOSTIC NUCLEAR MEDICINE SEGMENT COMMANDED THE LARGEST SHARE OF THE NUCLEAR MEDICINE MARKET IN 2017
  • FIGURE 16: PET RADIOPHARMACEUTICALS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 17: ALPHA EMITTERS WILL CONTINUE TO DOMINATE THE THERAPEUTIC NUCLEAR MEDICINE MARKET DURING THE FORECAST PERIOD
  • FIGURE 18: GEOGRAPHICAL SNAPSHOT OF THE NUCLEAR MEDICINE MARKET
  • FIGURE 19: THYROID SEGMENT IS EXPECTED TO REGISTER THE HIGHEST CAGR IN THE SPECT APPLICATIONS MARKET DURING THE FORECAST PERIOD
  • FIGURE 20: ONCOLOGY APPLICATIONS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE PET APPLICATIONS MARKET DURING THE FORECAST PERIOD
  • FIGURE 21: ENDOCRINE TUMORS APPLICATION SEGMENT IS EXPECTED TO REGISTER THE HIGHEST CAGR IN THE THERAPEUTIC APPLICATIONS MARKET DURING THE FORECAST PERIOD
  • FIGURE 22: NUCLEAR MEDICINE PROCEDURES MARKET, BY TYPE, 2018 VS. 2023 (THOUSAND PROCEDURES)
  • FIGURE 23: NORTH AMERICA TO DOMINATE THE NUCLEAR MEDICINE MARKET IN 2018
  • FIGURE 24: NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT
  • FIGURE 25: EUROPE: NUCLEAR MEDICINE MARKET SNAPSHOT
  • FIGURE 26: ASIA PACIFIC: NUCLEAR MEDICINE MARKET SNAPSHOT
  • FIGURE 27: ROW: NUCLEAR MEDICINE MARKET SNAPSHOT
  • FIGURE 28: KEY DEVELOPMENTS IN THE NUCLEAR MEDICINE MARKET, 2015-2018
  • FIGURE 29: MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2017
  • FIGURE 30: CARDINAL HEALTH: COMPANY SNAPSHOT (2017)
  • FIGURE 31: GE HEALTHCARE: COMPANY SNAPSHOT (2017)
  • FIGURE 32: LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT (2017)
  • FIGURE 33: BAYER: COMPANY SNAPSHOT (2017)
  • FIGURE 34: ADVANCED ACCELERATOR APPLICATIONS: COMPANY SNAPSHOT (2016)
目次
Product Code: PH 3590

"The nuclear medicine market is projected to grow at a CAGR of 5.9%"

The nuclear medicine market is projected to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018. Factors such as the growing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99, are driving market growth. However, the short half-life of radiopharmaceuticals, hospital budget cuts, and high equipment prices are likely to restrain market growth.

"The F-18 segment to dominate the PET nuclear medicine market during the forecast period"

Based on type, the nuclear medicine market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. The diagnostic radiopharmaceuticals have been segmented into SPECT and PET radiopharmaceuticals. PET radiopharmaceuticals have been further segmented into F-18, Ru-82, and other PET isotopes. In 2017, the F-18 segment accounted for the largest share of the nuclear medicine PET radiopharmaceuticals market. F-18 is the most commonly used PET radioisotope owing to its higher half-life (110 minutes) compared to other radioisotopes. F-18 is estimated to account for 98% of the total PET radioisotopes market.

"The thyroid application segment is expected to be the fastest growing SPECT applications segment"

The major application areas of SPECT nuclear medicine include cardiology, lymphoma, thyroid, neurology and others (prostate cancer diagnosis, bone scans, and white cell scans). The thyroid applications segment is expected to register the highest CAGR during the forecast period. Growth in this application segment is mainly driven by the rising demand for combinational SPECT/CT therapy owing to its enhanced imaging abilities. Moreover, with growth in the number of thyroid cancer cases, the use of radiopharmaceuticals for diagnosis of thyroid disorders is expected to increase in the next five years.

"In 2018, North America is expected to dominate the nuclear medicine market"

The nuclear medicine market is divided into four major regions- North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the nuclear medicine market. The major factors contributing to the large share of this segment include the development of novel technologies for radioisotope production, government support, and company initiatives in the region.

Asia Pacific is expected to register the highest CAGR during the forecast period. The major factors driving the growth of this regional segment include research initiatives in Japan and the rising installations of PET scanners in India and China.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1: 54%, Tier 2: 34%, and Tier 3: 12%
  • By Designation - C-level: 31%, Director Level: 19%, Others: 50%
  • By Region - North America: 46%, Europe: 25%, Asia Pacific: 18%, RoW: 11%

The major market players in the nuclear medicine market include: Cardinal Health (US), GE Healthcare (US), and Curium (France).

Research Coverage:

The report analyzes the market and aims at estimating the size and the future growth potential of this market based on various segments such as type, application, procedural volume, and region. The report also includes the competitive landscape of the key players along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned strategies.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on products and services offered by the top players in the global nuclear medicine market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the nuclear medicine market
  • Market Development: Comprehensive information about the lucrative emerging markets by type, end user, and region
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global nuclear medicine market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players in the global market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
      • 2.2.1.1. Key data from secondary sources
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key insights from primary sources
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. NUCLEAR MEDICINE: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE (2017)
  • 4.3. NUCLEAR MEDICINE MARKET SHARE, BY TYPE, 2018 VS. 2023
  • 4.4. GEOGRAPHICAL SNAPSHOT OF THE NUCLEAR MEDICINE MARKET

5. MARKET OVERVIEW

    • 5.1.1. INTRODUCTION
    • 5.1.2. MARKET DYNAMICS
    • 5.1.3. DRIVERS
      • 5.1.3.1. Increasing incidence and prevalence of target conditions
      • 5.1.3.2. Alpha radioimmunotherapy-based targeted cancer treatment
      • 5.1.3.3. Initiatives to lessen the demand-supply gap of Mo-99
    • 5.1.4. RESTRAINTS
      • 5.1.4.1. Short half-life of radiopharmaceuticals
    • 5.1.5. OPPORTUNITIES
      • 5.1.5.1. Use of radiopharmaceuticals in neurological applications
    • 5.1.6. CHALLENGES
      • 5.1.6.1. Hospital budget cuts and high equipment prices

6. NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. DIAGNOSTIC NUCLEAR MEDICINE
    • 6.2.1. SPECT RADIOPHARMACEUTICALS
      • 6.2.1.1. Tc-99m
      • 6.2.1.2. Tl-201
      • 6.2.1.3. Ga-67
      • 6.2.1.4. I-123
      • 6.2.1.5. Other SPECT isotopes
    • 6.2.2. PET RADIOPHARMACEUTICALS
      • 6.2.2.1. F-18
      • 6.2.2.2. Ru-82
      • 6.2.2.3. Other PET isotopes
  • 6.3. THERAPEUTIC NUCLEAR MEDICINE
    • 6.3.1. ALPHA EMITTERS
      • 6.3.1.1. Ra-223
    • 6.3.2. BETA EMITTERS
      • 6.3.2.1. I-131
      • 6.3.2.2. Y-90
      • 6.3.2.3. Sm-153
      • 6.3.2.4. Re-186
      • 6.3.2.5. Lu-177
      • 6.3.2.6. Other beta emitters
    • 6.3.3. BRACHYTHERAPY ISOTOPES
      • 6.3.3.1. I-125
      • 6.3.3.2. Ir-192
      • 6.3.3.3. Pd-103
      • 6.3.3.4. Cs-131
      • 6.3.3.5. Other brachytherapy isotopes

7. NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 7.1. INTRODUCTION
  • 7.2. DIAGNOSTIC APPLICATIONS
    • 7.2.1. SPECT APPLICATIONS
      • 7.2.1.1. Cardiology
      • 7.2.1.2. Lymphoma
      • 7.2.1.3. Neurology
      • 7.2.1.4. Thyroid
      • 7.2.1.5. Other SPECT applications
    • 7.2.2. PET APPLICATIONS
      • 7.2.2.1. Oncology
      • 7.2.2.2. Cardiology
      • 7.2.2.3. Neurology
      • 7.2.2.4. Other PET applications
  • 7.3. THERAPEUTIC APPLICATIONS
    • 7.3.1. THYROID
    • 7.3.2. BONE METASTASIS
    • 7.3.3. LYMPHOMA
    • 7.3.4. ENDOCRINE TUMORS
    • 7.3.5. OTHER THERAPEUTIC APPLICATIONS

8. NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

  • 8.1. INTRODUCTION
  • 8.2. DIAGNOSTIC PROCEDURES
    • 8.2.1. SPECT RADIOPHARMACEUTICALS
    • 8.2.2. PET RADIOPHARMACEUTICALS
  • 8.3. THERAPEUTIC PROCEDURES
    • 8.3.1. BETA EMITTERS
    • 8.3.2. ALPHA EMITTERS
    • 8.3.3. BRACHYTHERAPY ISOTOPES

9. NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. US
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. GERMANY
    • 9.3.2. FRANCE
    • 9.3.3. UK
    • 9.3.4. ITALY
    • 9.3.5. SPAIN
    • 9.3.6. ROE
  • 9.4. ASIA PACIFIC
  • 9.5. REST OF THE WORLD

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
  • 10.3. COMPETITIVE SCENARIO
    • 10.3.1. AGREEMENTS, PARTNERSHIPS, AND CONTRACTS
    • 10.3.2. PRODUCT APPROVALS
    • 10.3.3. FUNDING
    • 10.3.4. ACQUISITIONS
    • 10.3.5. EXPANSIONS
    • 10.3.6. OTHER DEVELOPMENTS

11. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*

  • 11.1. CARDINAL HEALTH
  • 11.2. GE HEALTHCARE (A FULLY-OWNED SUBSIDIARY OF GENERAL ELECTRIC COMPANY)
  • 11.3. CURIUM
  • 11.4. LANTHEUS MEDICAL IMAGING
  • 11.5. BAYER
  • 11.6. BRACCO IMAGING
  • 11.7. ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • 11.8. NORDION (A SUBSIDIARY OF STERIGENICS INTERNATIONAL)
  • 11.9. ADVANCED ACCELERATOR APPLICATIONS (AAA, ACQUIRED BY NOVARTIS)

*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. DISCUSSION GUIDE
  • 12.2. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.3. AVAILABLE CUSTOMIZATIONS
  • 12.4. RELATED REPORTS
  • 12.5. AUTHOR DETAILS
Back to Top